

Consensus Document on Improving Hypertension Management in Asian Patients, Taking Into Account Asian Characteristics

Kazuomi Kario, Chen-Huan Chen, Sungha Park, Chang-Gyu Park, Satoshi Hoshide, Hao-Min Cheng, Qi-Fang Huang, Ji-Guang Wang

Hypertension is the major cause of mortality and the leading cause of cardiovascular disease worldwide. Blood pressure (BP) lowering either by lifestyle modification or medication leads to a reduction in cardiovascular events. However, there are significant ethnic differences in the determinants of hypertension and in the risk of hypertension-related demographics of cardiovascular disease.¹⁻⁴ In Asian countries, stroke, especially hemorrhagic stroke, and nonischemic heart failure (HF) are more common than in Western countries. Stroke and HF are more closely related to hypertension than coronary artery disease or renal disease. In addition, data from the Asia Pacific Cohort Studies Collaboration show that the association between BP and cardiovascular disease is stronger in Asian patients than in white patients from Australia and New Zealand.^{5,6} In terms of the characteristics of determinants of hypertension, Asians are more likely to have higher salt sensitivity and salt intake than Western populations. Genetically, Asians are likely to have factors relating to salt-sensitive gene polymorphism of the renin-angiotensin system (RAS).⁷ In fact, Japanese people are more likely to develop pre-hypertension and hypertension even with a small increase in body mass index, and the body mass index associated with pre-hypertension was lower than that in Western countries.⁸

A previous survey of senior doctors in Asia demonstrated a need for Asian guidelines that take into account Asian characteristics of cardiovascular disease.⁹ Here, we have developed a consensus document for more optimal management of hypertension in East Asian people, which takes into consideration ethnic-specific characteristics.

Asian Characteristics of Hypertension and Cardiovascular Disease

Consensus Statements

1. Stroke, especially hemorrhagic stroke, and nonischemic HF are common outcomes of hypertension-related cardiovascular disease in Asia.
2. The association between BP and cardiovascular disease is stronger in Asia than in the West.

3. Higher salt sensitivity, even with mild obesity and higher salt intake, is an Asian characteristic of hypertension.

Out-of-Office BP

Consensus Statements

1. Out-of-office BP measurement is recommended for the detection of white-coat hypertension.
2. It is important to accurately detect and manage masked (or masked uncontrolled) hypertension.
3. The initial focus should be on morning BP, then nocturnal BP, in Asian populations.

One of the most important roles of measuring out-of-office BP is to exclude white-coat hypertension. Many publications have reported findings of no increased cardiovascular risk with white-coat hypertension compared with true normotension.^{10,11} In addition, the NICE guidelines (National Institute for Clinical Excellence) have recommended the use of ambulatory BP monitoring (ABPM) for detecting white-coat hypertension.¹²

There is accumulating evidence that masked (or masked uncontrolled) hypertension, defined by normal office BP and elevated out-of-office BP, provides an equivalent risk of cardiovascular events as sustained hypertension, defined by both elevated office BP and out-of-office BP. Evidence from the ARTEMIS database (Ambulatory Blood Pressure Registry Telemonitoring of Hypertension and Cardiovascular Risk) showed that masked hypertension and masked uncontrolled hypertension were more likely to be diagnosed in Asia than in any other region.¹³ This emphasizes the importance of detecting and managing masked hypertension and masked uncontrolled hypertension in Asians, as part of hypertension treatment. Furthermore, morning BP should be the initial focus for the management of out-of-office BP in Asians,¹⁴ for the following reasons: (1) both morning BP surge detected by ABPM and morning BP measured at home were predictors of cardiovascular outcome independent of office BP level in Japanese hypertensive patients.^{15,16} (2) Morning BP surge in Asian populations may be higher than in Western populations even after adjustment for age, office BP, and 24-hour BP.¹⁷ (3) Morning BP

From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan (K.K., S.H.); Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan (C.-H.C., H.-M.C.); Division of Cardiology, Cardiovascular Hospital, Yonsei Health System, Seoul, South Korea (S.P.); Division of Cardiology, College of Medicine, Korea University, Seoul, South Korea (C.-G.P.); and the Shanghai Institute of Hypertension and Centre for Epidemiological Studies and Clinical Trials Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (Q.-F.H., J.-G.W.).

This article was sent to Daniel W. Jones, Guest Editor, for review by expert referees, editorial decision, and final disposition.

Correspondence to Kazuomi Kario, Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. E-mail kkario@jichi.ac.jp

(*Hypertension*. 2018;71:375-382. DOI: 10.1161/HYPERTENSIONAHA.117.10238.)

© 2018 American Heart Association, Inc.

Hypertension is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.117.10238

measured at home provided superior model discrimination for stroke incidence compared with evening BP after adjustment for covariates, including office BP, in the Japanese general practice population.¹⁸ (4) The multicenter HOMED-BP study (Hypertension Objective Treatment Based on Measurement by Electrical Devices of BP) showed the feasibility of adjusting antihypertensive drug treatment based on morning BP measured at home in Japanese hypertensive patients.¹⁹

Moreover, even in the situation of controlled morning BP (<135/85 mmHg) at home, approximately one quarter of patients exhibited masked nocturnal hypertension ($\geq 120/70$ mmHg) detected by home BP monitoring (HBPM).²⁰ Some studies have suggested that nocturnal hypertension is associated with high sodium intake and salt sensitivity, which may seem to be specific characteristics of hypertension in Asian populations.²¹ International epidemiological data have demonstrated that increased nocturnal BP is a powerful predictor of cardiovascular outcomes, especially in treated hypertensive patients.^{22,23} In addition, isolated nocturnal hypertension may be more prevalent in Asians than Europeans.²³ Thus, the management of both morning and nocturnal BP is important in Asian populations.

Morning Hypertension

Consensus Statements

1. Morning BP surge, defined as the change from night-time sleeping to morning waking hours, or the mean level of BP readings within 1 to 2 hours of waking, confers cardiovascular risk independent of the 24-hour ambulatory BP.
2. Morning BP control can and should be improved with the use of long-acting antihypertensive drugs in appropriate, often full, dosages and in proper combinations.

Both ischemic stroke and coronary events often occur in the early morning hours.^{24,25} BP usually also peaks in the morning.²⁶ These parallel phenomena suggest that high BP in the morning may be particularly important for the occurrence of cardiovascular events. A prospective observational study in Japan first demonstrated that morning BP surge, defined as a systolic BP increase from night-time sleeping to early morning waking hours, was associated with stroke, which was independent of the mean 24-hour ambulatory systolic BP and other cardiovascular risk factors.¹⁵ The finding was corroborated by a much larger study of patients in IDACO (International Database of ABP in Relation to Cardiovascular Outcome).²⁷

The risk of morning surge is mainly attributable to elevated morning BP.²⁸ The level of morning BP, which can be assessed by either ABPM or HBPM, is used to define morning hypertension. Uncontrolled morning hypertension is common even in patients with controlled clinic BP and is associated with an increased risk of cardiovascular events.²⁹

Morning BP may be particularly relevant for the management of hypertension in Asia. A recent study demonstrated that Japanese patients had a much larger morning BP surge and higher morning BP than European patients.¹⁷ This ethnic difference is not completely understood. Pathophysiological mechanisms, such as activation of the sympathetic nervous system³⁰ or increased dietary sodium intake, may be involved.³¹ However, inadequate use of antihypertensive drugs, such as

the use of short- or intermediate-acting drugs, underdosing of drugs, or underuse of combination antihypertensive therapy, might be the main cause of uncontrolled morning hypertension in Asia.³² In an expert recommendation published in 2014, the Council on Hypertension of the Chinese Society of Cardiology recommended the use of long-acting drugs in appropriate (often full) dosages, and in proper combinations, for morning BP control.³³ If not controlled by these therapeutic approaches, bedtime dosing of the antihypertensive drug can be considered. The discussion was recently expanded to Asia,¹⁴ and a consensus statement by an expert panel in Asia was published.³⁴

Vascular Aging

Consensus Statements

1. Vascular aging is expected to become the dominant phenotype of hypertension in many countries, especially in Asia.
2. Future randomized controlled trials are required to support that the diagnosis and monitoring of vascular aging in hypertension are best managed with the central BP strategy.

Vascular aging, characterized by increased arterial stiffness and wave reflection, is a major risk factor for the development of hypertension, especially in older subjects.³⁵ Vascular aging-related hypertension is characterized by a high pulse pressure at the central aorta.³⁵ Central pulse pressure is determined by both aortic stiffness and aortic root geometry.³⁵ A smaller aortic root diameter results in higher aortic characteristic impedance which may, in turn, increase the pulse pressure at the aortic root.³⁵⁻³⁷

Asian patients usually have a smaller aortic root diameter than white patients, partly because of a smaller body size.³⁸ However, Asian patients may have a larger aortic root diameter than white patients after adjustment for age, height, and weight.³⁹ Therefore, Asian populations, compared with Western populations, may have a particular predisposition to increased central aortic pulse pressure because of the relatively larger diameter and thinner media at the proximal aorta that modulates the interaction between ventricular ejection and arterial load.⁴⁰ Asians tend to be shorter than their Western counterparts, which contributes to increased augmentation of central pulse pressure from peripheral arterial wave reflections,⁴¹ an independent determinant of incident hypertension.⁴²

The Asian population is aging rapidly. Asians also generally have smaller stature and may have a greater wall stress and stiffness at the proximal aorta than white populations. Putting these 3 factors into the context of vascular aging suggests that vascular aging may have a greater significance on hypertension outcomes of Asian patients than Western patients.

Ideally, central BP should be monitored in aging Asian populations to accurately diagnose isolated central hypertension. However, there is ongoing controversy on whether the lack of consistently higher predictive value of central BP compared with brachial BP reflects a true pathophysiological issue or is potentially biased by an inadequate method used for central aortic BP measurement. There is a need for studies to compare central BP-guided therapeutic strategies with classic guideline-guided strategies for the prevention of cardiovascular events.

Elderly

Consensus Statements

1. The recommended BP target for the older hypertensive population is <140/90 mmHg.
2. However, when patients have an increased risk of hypotensive or renal side effects, or electrolyte abnormalities, a goal of <150/90 mmHg may be considered.
3. To achieve BP goal and to prevent stroke and HF in the older population, calcium channel blockers (CCBs), RAS blockers, and diuretics are recommended.

The definition of the older adult varies from >60 to >75 years in clinical trials and between the various hypertension management guidelines.^{43–47} Most guidelines agree that the very old should be defined as >80 years, and in these patients, drug treatment should be titrated cautiously to avert adverse responses and excessive BP lowering.

People of older age commonly have increased sympathetic nervous system activity, increased BP variability, impaired BP homeostasis such as orthostatic hypotension or postprandial hypotension, and increased salt sensitivity.^{48–50} Hypertension in older individuals is characterized by a predominance of isolated systolic hypertension, and systolic BP is the main determinant of risk and the target of drug therapy in this population. Multiple mechanisms, including stiffening of the large arteries, endothelial dysfunction, cardiac remodeling, autonomic dysregulation, and renal aspects, contribute to the high prevalence of hypertension in older patients and increases cardiovascular morbidity and mortality. Older hypertensive adults experience cardiovascular events at a rate of 2× to 3× higher than younger patients with the same levels of BP.⁵¹

Therefore, controlling BP to target in the older hypertensive population is important. This is recommended based on the strength of data which have shown that target BP in older patients should be at least <140/90 mmHg.^{52,53} The intensive treatment of SPRINT (Systolic Blood Pressure Intervention Trial) patients aged ≥75 years, targeting a systolic BP of <120 mmHg as compared with <140 mmHg, achieved a significant 34% reduction in fatal and nonfatal cardiovascular events and a 33% reduction in all-cause mortality.^{54,55} Meanwhile, the HYVET study (Hypertension in the Very Elderly Trial) suggested that a goal of <150/90 mmHg was reasonable in patients aged ≥80 years.⁵⁶

If the systolic BP target for older patients remains at <150 mmHg, the available evidence indicates that, compared with a systolic BP of <140 mmHg, the relative risk of stroke would be increased by 30% to 40%. Nevertheless, a systolic BP target of <150 mmHg may be appropriate for older patients who have an increased risk of hypotensive or renal side effects or electrolyte abnormalities. In the 2017 American (American College of Cardiology/American Heart Association) guidelines for the prevention, detection, evaluation, and management of high BP in adults, it was generally recommended that initiation of antihypertensive therapy should be undertaken cautiously in older people, orthostatic hypotension, and falls should be monitored.⁵⁷

In clinical practice, a staged approach for BP goal attainment may be recommended in older hypertensive patients. The first systolic BP target would be <150 mmHg; then, if tolerated and achievable, <140 mmHg; then, ideally, if tolerated and achievable, <130 mmHg.⁵⁸ This final goal is in line

with the 2017 American College of Cardiology/American Heart Association guideline, which recommended a systolic BP treatment goal of <130 mmHg for noninstitutionalized ambulatory community-dwelling adults (≥65 years) with an average systolic BP of ≥130 mmHg.⁵⁷

Because stroke is the most important cause of cardiovascular mortality in older Asian populations,⁵⁹ more thorough BP regulation is needed in this group. These populations are also more prone to a higher incidence of side effects and an increased risk of BP variability than the general population, and, thus, measuring home BP in older subjects, in addition to usual clinic BP, is recommended where available. The pathophysiologic concept is important in the treatment of hypertension in older adults: in people with vascular aging and arterial stiffness, such as the elderly, BP is highly volume dependent; thus, these patients typically respond well to a low-dose diuretic or calcium antagonist.⁶⁰ Most older patients require multiple antihypertensive agents to control BP. The angiotensin-converting enzyme inhibitors or angiotensin receptor blockers can be considered for patients with diabetes mellitus and if there are compelling indications, such as chronic systolic HF, post-myocardial infarction, or chronic kidney disease (CKD).⁶¹

Type 2 Diabetes Mellitus

Consensus Statement

1. In Asians, a treatment goal of BP <130/80 mmHg can be considered in hypertensive subjects with type 2 diabetes mellitus.

In the ACCORD study (Action to Control Cardiovascular Risk in Diabetes), strict BP control, defined as a target systolic BP of <120 mmHg, failed to show benefit over usual BP control, defined as a target systolic BP of <140 mmHg.⁶² However, there was a significant 37% reduction in nonfatal stroke and 41% reduction in total stroke in the strict BP-lowering group.⁶² In a recent meta-analysis of 49 clinical trials of antihypertensive treatment involving 73 738 type 2 diabetic subjects, there was no evidence for benefit in reducing systolic BP to <130 mmHg except for stroke reduction.⁶³ In Asians, the predominant cardiovascular events associated with hypertension are strokes, whereas in whites, ischemic heart disease is the most frequent cardiovascular outcome.⁶⁴ Thus, the target systolic BP of 130 mmHg can be considered in Asian hypertensive subjects with type 2 diabetes mellitus.⁶⁵

Chronic Kidney Disease

Consensus Statements

1. The prevalence of CKD is higher in hypertensive patients than in the general population, and the prevalence of CKD associated with hypertension in Asian populations is increasing.
2. Hypertensive patients require more intensive out-of-office BP evaluation and comprehensive cardiovascular evaluation in the presence of CKD.
3. Intensive BP control is required for patients with CKD to preserve renal function and to prevent cardiovascular events.

In Asia, the prevalence of CKD is much higher in hypertensive patients than in the overall population.^{66–69} According to a Chinese national survey, the prevalence of CKD was 18.9%

in hypertensive patients (n=16691) and 10.8% in the overall population (n=47204).⁶⁶ Moreover, the prevalence of concomitant CKD and hypertension is increasing in Asia. Surveys performed in Japan in 1974, 1988, and 2002 showed that the prevalence of CKD increased in both treated (18.8%, 23.8%, and 36.1%, respectively) and untreated (16.6%, 17.5%, and 28.8%, respectively) hypertensive patients.⁷⁰

In the presence of CKD, hypertensive patients often require more intensive BP measurement by ABPM and HBPM because they may have greater BP variability and higher nighttime BP.^{71–74} To accurately evaluate BP and detect treatment-naïve or uncontrolled nocturnal hypertension in patients with CKD, ABPM must be performed.^{75,76} HBPM might be helpful in the screening of nocturnal hypertension.² It is, therefore, imperative to perform more out-of-office BP measurements in Asian patients with CKD.

Most current hypertension and CKD guidelines recommend more intensive BP lowering in hypertensive patients with CKD.^{43,77–85} In Asians, the major complication of hypertension is stroke; thus, the BP target might be different to that for Western populations although this needs to be further investigated. Intensive BP control to 130/80 mmHg is often required to prevent CKD progression and stroke.

Atrial Fibrillation

Consensus Statement

1. In hypertensive subjects with atrial fibrillation (AF) undergoing anticoagulation, a target systolic BP of <130 mmHg can be considered to minimize the risk of hemorrhagic stroke.

The presence of hypertension significantly increases the risk of stroke and excess bleeding in patients with AF; as such, strict BP control and anticoagulation are needed to minimize cardiovascular risk.^{86–88} Hypertensive patients with AF are unique to other hypertensive subjects in that most patients receive anticoagulation to minimize the risk of embolic complications. Therefore, the target BP in this subset of patients may be different to that of other hypertensive patients. Post hoc analyses or analyses from registry studies have suggested that, in patients receiving antiplatelet or anticoagulation therapy, a lower BP target may be needed to minimize the bleeding risk. In the post hoc analysis of PROGRESS (Perindopril Protection Against Recurrent Stroke Study), in patients with a history of cerebrovascular disease (with or without AF), active treatment with perindopril, with or without indapamide, in patients already receiving antithrombotic therapy resulted in a reduction of intracranial bleeding by 46%, with the lowest risk of bleeding being associated with a median systolic BP of 113 mmHg.⁸⁹ Also, in the J-Rhythm registry of 7406 patients with nonvalvular AF followed for 2 years, a systolic BP \geq 136 mmHg was an independent risk factor for thromboembolism and major hemorrhage.⁹⁰ Therefore, a target BP of 130 mmHg can be considered for minimizing the risk of intracranial hemorrhage in hypertensive subjects with AF who are also receiving anticoagulation therapy. This has added importance for Asian patients, who are more prone to stroke and bleeding complications arising from anticoagulation treatment.

Secondary Prevention of Stroke

Consensus Statements

1. Stroke is among the leading causes of death and represents a large disease burden in East Asian countries, and it may be related to high sodium intake.
2. The relationship between BP reduction and the risk of recurrent stroke is less pronounced than in primary prevention, but BP reduction still substantially benefits patients who survive stroke events.
3. Evidence from randomized, controlled trials supports the use of diuretic-based treatment, especially when combined with an angiotensin-converting enzyme inhibitor, for the secondary prevention of stroke and vascular events in poststroke patients.
4. High BP and increased BP variability are associated with worse outcomes in patients after stroke. CCBs, with their superior effectiveness for the control of BP variability, can be considered in the management of poststroke hypertension.

In 2014, the mortality attributed to cerebrovascular diseases ranked fourth in Japan, third in mainland China, and third in Taiwan, among all causes of death. In addition, Asian countries had the highest age- and sex-adjusted stroke mortality rate.⁹¹ High sodium intake increases BP,⁹² a risk factor for cardiovascular disease; thus, the high stroke mortality rate in Asia may be closely associated with dietary patterns of sodium intake in this region.^{92,93} Reduction in sodium intake can effectively reduce BP in a linear fashion, in which every 2.3 g/d sodium reduction can lead to a 3.82-mmHg decrease in systolic BP.⁹² For stroke survivors, the relationship between BP reduction and the risk of recurrent stroke⁹⁴ was less pronounced than that in primary prevention studies,⁹⁵ but adequate BP reduction can still substantially benefit these patients.^{94,96}

Evidence from randomized, controlled trials supports the use of diuretic-based treatment, especially when combined with an angiotensin-converting enzyme inhibitor, for the secondary prevention of recurrent stroke and vascular events.^{94,96,97} This finding implies that the adverse effect of high sodium intake may be reduced using a diuretic-based strategy. In addition, high BP and increased BP variability are associated with worse outcomes in patients after stroke.^{98–101} A systematic review and meta-analysis investigating the effects of antihypertensive drug class on BP variability showed that interindividual variation in systolic BP, of which 50% resulted from within-individual visit-to-visit systolic BP variability, was most reduced by CCBs.¹⁰² As such, CCBs can be considered useful for managing poststroke hypertension.¹⁰²

Antihypertensive Treatment

Consensus Statements

1. Strict BP control for the 24-hour period is important, especially in Asia.
2. A home BP-guided approach is the first practical step for strict BP control on the individual level.
3. Use of a long-acting and potent CCB and RAS inhibitor, with or without a diuretic, to control BP is preferable.

Strict BP control for the 24-hour period is important, especially in Asia.¹ SPRINT clearly demonstrated the benefit of strict BP control in high-risk or older hypertensive patients.¹⁰³ The

benefits of BP lowering may be even greater in Asian patients than in Western populations because the effect of BP lowering on stroke and HF is greater than on coronary artery disease.⁵³

A home BP-guided approach, especially targeting morning hypertension, is the first step for 24-hour BP control in the individual.^{14,81,104} For HBPM, a systolic BP target of 125 mmHg in the morning is probably ideal.¹⁰⁵ Based on the HONEST study (Home Blood Pressure Measurement With Olmesartan Naive Patients to Establish Standard Target Blood Pressure)^{16,29} and HOMED-BP study,¹⁹ the achieved home BP during anti-hypertensive treatment was a better predictor than office BP, suggesting that the lower the home BP, the better the cardiovascular prognosis until the systolic BP of <125 mmHg. However, an adequately powered randomized controlled clinical trial is needed to prove this. Use of a long-acting and potent CCB and RAS inhibitor, with or without a diuretic, is preferable when considering the characteristics of Asian hypertensive patients, such as higher salt intake and higher salt sensitivity.^{1,14,103} A long-acting CCB is effective for lowering office, home morning, and 24-hour ambulatory BP, reducing exaggerated BP variability independently of salt intake and salt sensitivity.^{106–108} Angiotensin receptor blockers are also effective for lowering office BP and home morning BP when used as monotherapy or in combination with a CCB or diuretic.^{109–111} Even within the same class, CCBs and RAS inhibitors vary in their potential to lower 24-hour BP. These differences may be enhanced in the salt-sensitive Asian population that typically also has a higher salt intake. A low-dose diuretic on top of a RAS inhibitor plus CCB^{110,112} is an effective strategy to reduce BP.

β -Blockers may be useful in special populations, such as in young hypertensive patients with increased heart rate or patients with coronary artery disease, AF, or HF.⁸¹ Renal denervation may be effective for treating uncontrolled nocturnal or morning hypertension,¹¹³ especially in Asian patients,¹¹⁴ because Asian patients with drug-resistant hypertension have higher morning and nocturnal BP variability than Western patients, even when office BP is comparable.¹¹⁵

Conclusions

Hypertension management that takes Asian characteristics into account can achieve more effective prevention of cardiovascular disease and target-organ damage in Asian countries. Because there is generally less evidence in Asian patients, however, more clinical studies to clarify Asian-specific characteristics for the management of hypertension are needed.

Acknowledgments

We acknowledge Dr Cathy Chow (Calico Communications) for editorial support, which was funded by Daiichi Sankyo Co. Ltd. and Haruo Anzai (Daiichi Sankyo Co. Ltd.) and Mitsunori Sugiyama (Daiichi Sankyo Co. Ltd.) for their logistical support.

Sources of Funding

The meetings held between the authors to discuss and prepare this manuscript were funded by an unrestricted educational grant from Daiichi Sankyo Co. Ltd.

Disclosures

J.-G. Wang received lecture and consulting fees from Bayer, Daiichi Sankyo, MSD, Pfizer, Sanofi, Servier, and Takeda. K. Kario received

research funding from Teijin Pharma Limited, Omron Healthcare Co., Ltd., Fukuda Denshi, Bayer Yakuhin Ltd., A & D Co., Ltd., Daiichi Sankyo Company, Limited, Mochida Pharmaceutical Co., Ltd, EA Pharma, Boehringer Ingelheim Japan Inc, Tanabe Mitsubishi Pharma Corporation, Shionogi & Co., Ltd., MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Bristol-Myers Squibb K.K., and honoraria from Takeda Pharmaceutical Company Limited and Omron Healthcare Co., Ltd. The other authors report no conflicts.

References

1. Kario K. Evidence and perspectives on the 24-hour management of hypertension: hemodynamic biomarker-initiated 'anticipation medicine' for zero cardiovascular event. *Prog Cardiovasc Dis*. 2016;59:262–281. doi: 10.1016/j.pcad.2016.04.001.
2. Kario K, Tomitani N, Matsumoto Y, Hamasaki H, Okawara Y, Kondo M, Nozue R, Yamagata H, Okura A, Hoshide S. Research and development of information and communication technology-based home blood pressure monitoring from morning to nocturnal hypertension. *Ann Glob Health*. 2016;82:254–273. doi: 10.1016/j.aogh.2016.02.004.
3. Park JB, Kario K, Wang JG. Systolic hypertension: an increasing clinical challenge in Asia. *Hypertens Res*. 2015;38:227–236. doi: 10.1038/hr.2014.169.
4. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, Watanabe M, Kadota A, Okuda N, Kadowaki T, Nakamura Y, Okamura T. Cardiovascular disease and risk factors in Asia: a selected review. *Circulation*. 2008;118:2702–2709. doi: 10.1161/CIRCULATIONAHA.108.790048.
5. Lawes CM, Bennett DA, Parag V, Woodward M, Whitlock G, Lam TH, Suh I, Rodgers A; Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. *Hypertension*. 2003;42:69–75. doi: 10.1161/01.HYP.0000075083.04415.4B.
6. Arima H, Murakami Y, Lam TH, Kim HC, Ueshima H, Woo J, Suh I, Fang X, Woodward M; Asia Pacific Cohort Studies Collaboration. Effects of prehypertension and hypertension subtype on cardiovascular disease in the Asia-Pacific Region. *Hypertension*. 2012;59:1118–1123. doi: 10.1161/HYPERTENSIONAHA.111.187252.
7. Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. *Hypertens Res*. 2003;26:521–525.
8. Ishikawa Y, Ishikawa J, Ishikawa S, Kayaba K, Nakamura Y, Shimada K, Kajii E, Pickering TG, Kario K; Jichi Medical School Cohort Investigators Group. Prevalence and determinants of prehypertension in a Japanese general population: the Jichi Medical School Cohort Study. *Hypertens Res*. 2008;31:1323–1330. doi: 10.1291/hypres.31.1323.
9. Hoshide S, Wang JG, Park S, Chen CH, Cheng HM, Huang QF, Park CG, Kario K. Treatment considerations of clinical physician on hypertension management in Asia. *Curr Hypertens Rev*. 2016;12:164–168.
10. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. *J Am Coll Cardiol*. 2005;46:508–515. doi: 10.1016/j.jacc.2005.03.070.
11. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. *Hypertension*. 1994;24:793–801.
12. Excellence. NIfHaC. Hypertension: Clinical Management of Primary Hypertension in Adults. Cg127. Available at: <http://guidance.nice.org.uk/CG127/Guidance/pdf/English>. 2011. Accessed July 7, 2017.
13. Omboni S, Aristizabal D, De la Sierra A, et al; ARTEMIS (international Ambulatory blood pressure Registry: TELeMonitoring of hypertension and cardiovascular rISk project) Investigators. Hypertension types defined by clinic and ambulatory blood pressure in 14143 patients referred to hypertension clinics worldwide. Data from the ARTEMIS study. *J Hypertens*. 2016;34:2187–2198. doi: 10.1097/HJH.0000000000001074.
14. Wang JG, Kario K, Park JB, Chen CH. Morning blood pressure monitoring in the management of hypertension. *J Hypertens*. 2017;35:1554–1563. doi: 10.1097/HJH.0000000000001379.
15. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation*. 2003;107:1401–1406.

16. Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y, Kobayashi F, Shimada K. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. *Hypertension*. 2014;64:989–996. doi: 10.1161/HYPERTENSIONAHA.114.04262.
17. Hoshide S, Kario K, de la Sierra A, Bilo G, Schillaci G, Banegas JR, Gorostidi M, Segura J, Lombardi C, Omboni S, Ruilope L, Mancia G, Parati G. Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study. *Hypertension*. 2015;66:750–756. doi: 10.1161/HYPERTENSIONAHA.115.05958.
18. Hoshide S, Yano Y, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, Matsui Y, Nakamura A, Fukutomi M, Eguchi K, Ishikawa J, Kario K; J-HOP Study Group. Morning and evening home blood pressure and risks of incident stroke and coronary artery disease in the Japanese general practice population: the Japan Morning Surge-Home Blood Pressure Study. *Hypertension*. 2016;68:54–61. doi: 10.1161/HYPERTENSIONAHA.116.07201.
19. Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, Thijs L, Staessen JA, Imai Y; Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP). Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. *Hypertens Res*. 2012;35:1102–1110. doi: 10.1038/hr.2012.125.
20. Kario K, Hoshide S, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, Yano Y, Eguchi K, Matsui Y, Shimizu M, Ishikawa J, Ishikawa S; J-HOP Study Group. Sleep blood pressure self-measured at home as a novel determinant of organ damage: Japan Morning Surge Home Blood Pressure (J-HOP) Study. *J Clin Hypertens (Greenwich)*. 2015;17:340–348. doi: 10.1111/jch.12500.
21. Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. *Hypertens Res*. 2010;33:515–520. doi: 10.1038/hr.2010.47.
22. Boggia J, Li Y, Thijs L, et al; International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) Investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. *Lancet*. 2007;370:1219–1229. doi: 10.1016/S0140-6736(07)61538-4.
23. Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark. *Hypertension*. 2013;61:278–283. doi: 10.1161/HYPERTENSIONAHA.111.00217.
24. Marler JR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, Hier DB, Wolf PA, Caplan LR, Foulkes MA. Morning increase in onset of ischemic stroke. *Stroke*. 1989;20:473–476.
25. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T, Sobel BE, Willerson JT, Braunwald E; MILIS Study Group. Circadian variation in the frequency of onset of acute myocardial infarction. *N Engl J Med*. 1985;313:1315–1322.
26. Kuwajima I, Mitani K, Miyao M, Suzuki Y, Kuramoto K, Ozawa T. Cardiac implications of the morning surge in blood pressure in elderly hypertensive patients: relation to arising time. *Am J Hypertens*. 1995;8:29–33. doi: 10.1016/0895-7061(94)00154-4.
27. Li Y, Thijs L, Hansen TW, et al; International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. *Hypertension*. 2010;55:1040–1048. doi: 10.1161/HYPERTENSIONAHA.109.137273.
28. Kario K. Time for focus on morning hypertension: pitfall of current antihypertensive medication. *Am J Hypertens*. 2005;18(2 pt 1):149–151. doi: 10.1016/j.amjhyper.2004.09.007.
29. Kario K, Saito I, Kushiro T, Teramukai S, Tomono Y, Okuda Y, Shimada K. Morning home blood pressure is a strong predictor of coronary artery disease: the HONEST Study. *J Am Coll Cardiol*. 2016;67:1519–1527. doi: 10.1016/j.jacc.2016.01.037.
30. Lambert EA, Chatzivlastou K, Schlaich M, Lambert G, Head GA. Morning surge in blood pressure is associated with reactivity of the sympathetic nervous system. *Am J Hypertens*. 2014;27:783–792. doi: 10.1093/ajh/hpt273.
31. Osanai T, Okuguchi T, Kamada T, Fujiwara N, Kosugi T, Saitoh G, Katoh T, Nakano T, Takahashi K, Guan W, Okumura K. Salt-induced exacerbation of morning surge in blood pressure in patients with essential hypertension. *J Hum Hypertens*. 2000;14:57–64.
32. Morgan T. Adequate blood pressure control: perception and reality. *Eur Heart J*. 1997;18 (suppl E):E9–E13.
33. Council on Hypertension of the Chinese Society of Cardiology. Chinese expert consensus on early morning blood pressure. *Chin J Cardiol*. 2014;42:721–725.
34. Wang JG, Kario K, Chen CH, Park JB, Hoshide S, Huo Y, Lee HY, Li Y, Mogi M, Munakata M, Park S, Zhu D. Management of morning hypertension: a Consensus Statement of an Asian Expert Panel. *J Clin Hypertens*. 2017. In press.
35. Cheng HM, Park S, Huang Q, Hoshide S, Wang JG, Kario K, Park CG, Chen CH; Characteristics on the Management of Hypertension in Asia - Morning Hypertension Discussion Group (COME Asia MHDG). Vascular aging and hypertension: implications for the clinical application of central blood pressure. *Int J Cardiol*. 2017;230:209–213. doi: 10.1016/j.ijcard.2016.12.170.
36. Mitchell GF, Wang N, Palmisano JN, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS. Hemodynamic correlates of blood pressure across the adult age spectrum: noninvasive evaluation in the Framingham Heart Study. *Circulation*. 2010;122:1379–1386. doi: 10.1161/CIRCULATIONAHA.109.914507.
37. Farasat SM, Morrell CH, Scuteri A, Ting CT, Yin FC, Spurgeon HA, Chen CH, Lakatta EG, Najjar SS. Pulse pressure is inversely related to aortic root diameter implications for the pathogenesis of systolic hypertension. *Hypertension*. 2008;51:196–202. doi: 10.1161/HYPERTENSIONAHA.107.099515.
38. Yoon SH, Ohno Y, Araki M, et al. Comparison of aortic root anatomy and calcification distribution between Asian and Caucasian patients who underwent transcatheter aortic valve implantation. *Am J Cardiol*. 2015;116:1566–1573. doi: 10.1016/j.amjcard.2015.08.021.
39. Virmani R, Avolio AP, Mergner WJ, Robinowitz M, Herderick EE, Cornhill JF, Guo SY, Liu TH, Ou DY, O'Rourke M. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. *Am J Pathol*. 1991;139:1119–1129.
40. Avolio A. Genetic and environmental factors in the function and structure of the arterial wall. *Hypertension*. 1995;26:34–37.
41. Reeve JC, Abhayaratna WP, Davies JE, Sharman JE. Central hemodynamics could explain the inverse association between height and cardiovascular mortality. *Am J Hypertens*. 2014;27:392–400. doi: 10.1093/ajh/hpt222.
42. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic stiffness, blood pressure progression, and incident hypertension. *JAMA*. 2012;308:875–881. doi: 10.1001/2012.jama.10503.
43. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311:507–520. doi: 10.1001/jama.2013.284427.
44. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC); ESH/ESC Task Force for the Management of Arterial Hypertension. *J Hypertens*. 2013;31:1925–1938.
45. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). *Hypertens Res*. 2008;31:2115–2127. doi: 10.1291/hyres.31.2115.
46. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. *Hypertension*. 2010;56:196–202. doi: 10.1161/HYPERTENSIONAHA.109.146035.
47. Chiang CE, Wang TD, Lin TH, et al. The 2017 focused update of the guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the management of hypertension. *Acta Cardiol Sin*. 2017;33:213–225.
48. Esler M, Hastings J, Lambert G, Kaye D, Jennings G, Seals DR. The influence of aging on the human sympathetic nervous system and brain norepinephrine turnover. *Am J Physiol Regul Integr Comp Physiol*. 2002;282:R909–R916. doi: 10.1152/ajpregu.00335.2001.
49. Monahan KD. Effect of aging on baroreflex function in humans. *Am J Physiol Regul Integr Comp Physiol*. 2007;293:R3–R12. doi: 10.1152/ajpregu.00031.2007.
50. Zemel MB, Sowers JR. Salt sensitivity and systemic hypertension in the elderly. *Am J Cardiol*. 1988;61:7H–12H.
51. Virdis A, Bruno RM, Neves MF, Bernini G, Taddei S, Ghiadoni L. Hypertension in the elderly: an evidence-based review. *Curr Pharm Des*. 2011;17:3020–3031.

52. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. *Lancet*. 2016;387:435–443. doi: 10.1016/S0140-6736(15)00805-3.
53. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016;387:957–967. doi: 10.1016/S0140-6736(15)01225-8.
54. Williamson JD, Supiano MA, Applegate WB, et al; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. *JAMA*. 2016;315:2673–2682. doi: 10.1001/jama.2016.7050.
55. Bavishi C, Bangalore S, Messerli FH. Outcomes of intensive blood pressure lowering in older hypertensive patients. *J Am Coll Cardiol*. 2017;69:486–493. doi: 10.1016/j.jacc.2016.10.077.
56. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*. 2008;358:1887–1898. doi: 10.1056/NEJMoa0801369.
57. Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published online ahead of print November 13, 2017]. *Hypertension*. <http://hyper.ahajournals.org/content/hypertensionaha/early/2017/11/10/HYP.0000000000000065.full.pdf>.
58. Benetos A, Rossignol P, Cherubini A, Joly L, Grodzicki T, Rajkumar C, Strandberg TE, Petrovic M. Polypharmacy in the aging patient: management of hypertension in octogenarians. *JAMA*. 2015;314:170–180. doi: 10.1001/jama.2015.7517.
59. Kim YD, Jung YH, Saposnik G. Traditional risk factors for stroke in East Asia. *J Stroke*. 2016;18:273–285. doi: 10.5853/jos.2016.00885.
60. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. *Cochrane Database Syst Rev*. 2009;CD000028.
61. Bavishi C, Goel S, Messerli FH. Isolated systolic hypertension: an update after SPRINT. *Am J Med*. 2016;129:1251–1258. doi: 10.1016/j.amjmed.2016.08.032.
62. Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1575–1585. doi: 10.1056/NEJMoa1001286.
63. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. *BMJ*. 2016;352:i1717.
64. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S; Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens*. 2003;21:707–716. doi: 10.1097/01.hjh.0000052492.18130.07.
65. Park S, Kario K, Park CG, Huang QF, Cheng HM, Hoshide S, Wang JG, Chen CH; Characteristics On the Management of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG). Target blood pressure in patients with diabetes: Asian perspective. *Yonsei Med J*. 2016;57:1307–1311. doi: 10.3349/ymj.2016.57.6.1307.
66. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. *Lancet*. 2012;379:815–822. doi: 10.1016/S0140-6736(12)60033-6.
67. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. *Clin Exp Nephrol*. 2009;13:621–630. doi: 10.1007/s10157-009-0199-x.
68. Park JI, Baek H, Jung HH. Prevalence of chronic kidney disease in Korea: the Korean National Health and Nutritional Examination Survey 2011–2013. *J Korean Med Sci*. 2016;31:915–923. doi: 10.3346/jkms.2016.31.6.915.
69. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang PH, Hsu CC, Sung PK, Hsu YH, Wen SF. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. *Lancet*. 2008;371:2173–2182. doi: 10.1016/S0140-6736(08)60952-6.
70. Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, Hata J, Tsuruya K, Iida M, Kiyohara Y. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama Study. *Nephrol Dial Transplant*. 2010;25:2557–2564. doi: 10.1093/ndt/gfq062.
71. Parati G, Ochoa JE, Bilo G, et al; European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA). Hypertension in chronic kidney disease part 2: role of ambulatory and home blood pressure monitoring for assessing alterations in blood pressure variability and blood pressure profiles. *Hypertension*. 2016;67:1102–1110. doi: 10.1161/HYPERTENSIONAHA.115.06896.
72. Fukuda M, Mizuno M, Yamanaka T, Motokawa M, Shirasawa Y, Nishio T, Miyagi S, Yoshida A, Kimura G. Patients with renal dysfunction require a longer duration until blood pressure dips during the night. *Hypertension*. 2008;52:1155–1160. doi: 10.1161/HYPERTENSIONAHA.108.115329.
73. Fukuda M, Kimura G. Salt sensitivity and nondippers in chronic kidney disease. *Curr Hypertens Rep*. 2012;14:382–387. doi: 10.1007/s11906-012-0286-3.
74. Li Y, Wang JG, Gao P, Guo H, Nawrot T, Wang G, Qian Y, Staessen JA, Zhu D. Are published characteristics of the ambulatory blood pressure generalizable to rural Chinese? The JingNing population study. *Blood Press Monit*. 2005;10:125–134.
75. Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, Greene T, Appel L, Phillips RA; African American Study of Kidney Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. *Hypertension*. 2009;53:20–27. doi: 10.1161/HYPERTENSIONAHA.108.115154.
76. Yano Y, Kario K. Nocturnal blood pressure and cardiovascular disease: a review of recent advances. *Hypertens Res*. 2012;35:695–701. doi: 10.1038/hr.2012.26.
77. Chiang CE, Wang TD, Ueng KC, et al. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. *J Chin Med Assoc*. 2015;78:1–47. doi: 10.1016/j.jcma.2014.11.005.
78. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013;3:1–150.
79. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013;34:2159–2219. doi: 10.1093/eurheartj/eh151.
80. Liu LS; Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. [2010 Chinese guidelines for the management of hypertension]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2011;39:579–615.
81. Shimamoto K, Ando K, Fujita T, et al; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). *Hypertens Res*. 2014;37:253–390. doi: 10.1038/hr.2014.20.
82. Shin J, Park JB, Kim KI, Kim JH, Yang DH, Pyun WB, Kim YG, Kim GH, Chae SC; Guideline Committee of the Korean Society of Hypertension. 2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. *Clin Hypertens*. 2015;21:3. doi: 10.1186/s40885-014-0014-1.
83. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens*. 2014;32:3–15. doi: 10.1097/HJH.0000000000000065.
84. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B; Guideline Development Group. Management of hypertension: summary of NICE guidance. *BMJ*. 2011;343:d4891. doi: 10.1136/bmj.d4891.
85. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. *Diabetes Care*. 2014;37:2864–2883.
86. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. *J Am Coll Cardiol*. 1998;31:1622–1626.
87. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. *Circulation*. 2005;112:1687–1691. doi: 10.1161/CIRCULATIONAHA.105.553438.
88. Lip GY, Frison L, Grind M; SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. *Eur Heart J*. 2007;28:752–759. doi: 10.1093/eurheartj/ehl504.

89. Arima H, Anderson C, Omae T, Woodward M, MacMahon S, Mancia G, Bousser MG, Tzourio C, Rodgers A, Neal B, Chalmers J; Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative Group. Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. *Stroke*. 2012;43:1675–1677. doi: 10.1161/STROKEAHA.112.651448.
90. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Otsuka T, Tomita H, Origasa H; J-RHYTHM Registry Investigators. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the J-RHYTHM registry. *J Am Heart Assoc*. 2016;5:e004075. doi: 10.1161/JAHA.116.004075.
91. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. *Circulation*. 2011;124:314–323. doi: 10.1161/CIRCULATIONAHA.111.018820.
92. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, Lim S, Danaei G, Ezzati M, Powles J; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group. Global sodium consumption and death from cardiovascular causes. *N Engl J Med*. 2014;371:624–634.
93. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. *J Hum Hypertens*. 2009;23:363–384. doi: 10.1038/jhh.2008.144.
94. Wang WT, You LK, Chiang CE, Sung SH, Chuang SY, Cheng HM, Chen CH. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and Bayesian network meta-analysis of randomized trials. *Medicine (Baltimore)*. 2016;95:e3302. doi: 10.1097/MD.0000000000003302.
95. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903–1913.
96. Katsanos AH, Filippatou A, Manios E, Deftereos S, Parisis J, Frogoudaki A, Vrettou AR, Ikonomidis I, Pikilidou M, Kargiotis O, Voumvourakis K, Alexandrov AV, Alexandrov AV, Tsivgoulis G. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. *Hypertension*. 2017;69:171–179. doi: 10.1161/HYPERTENSIONAHA.116.08485.
97. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. *Stroke*. 2003;34:2741–2748. doi: 10.1161/01.STR.0000092488.40085.15.
98. Kang J, Ko Y, Park JH, Kim WJ, Jang MS, Yang MH, Lee J, Lee J, Han MK, Gorelick PB, Bae HJ. Effect of blood pressure on 3-month functional outcome in the subacute stage of ischemic stroke. *Neurology*. 2012;79:2018–2024. doi: 10.1212/WNL.0b013e3182749eb8.
99. Wang Y, Wang J, Meng P, Liu N, Ji N, Zhang G, Xu B, Zhou X, Sun Y, Xu Y, Hui R, He M. Mid-term blood pressure variability is associated with clinical outcome after ischemic stroke. *Am J Hypertens*. 2017;30:968–977.
100. Tao Y, Xu J, Song B, Xie X, Gu H, Liu Q, Zhao L, Wang Y, Xu Y, Wang Y. Short-term blood pressure variability and long-term blood pressure variability: which one is a reliable predictor for recurrent stroke. *J Hum Hypertens*. 2017;31:568–573. doi: 10.1038/jhh.2017.32.
101. Manning L, Hirakawa Y, Arima H, et al; INTERACT2 Investigators. Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. *Lancet Neurol*. 2014;13:364–373. doi: 10.1016/S1474-4422(14)70018-3.
102. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet*. 2010;375:906–915. doi: 10.1016/S0140-6736(10)60235-8.
103. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103–2116. doi: 10.1056/NEJMoa1511939.
104. Kario K. *Essential Manual of 24-Hour Blood Pressure Management From Morning to Nocturnal Hypertension*. London, UK: Wiley-Blackwell; 2015: Chapter 1; 7–9.
105. Kario K. Hypertension: benefits of strict blood-pressure lowering in hypertension. *Nat Rev Cardiol*. 2016;13:125–126. doi: 10.1038/nrcardio.2016.13.
106. Eguchi K, Kario K, Hoshide Y, Hoshide S, Ishikawa J, Morinari M, Ishikawa S, Shimada K. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. *Am J Hypertens*. 2004;17:112–117.
107. Kario K, Hoshide S. Age-related difference in the sleep pressure-lowering effect between an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensives: the ACS1 Study. *Hypertension*. 2015;65:729–735. doi: 10.1161/HYPERTENSIONAHA.114.04935.
108. Wang JG, Kario K, Lau T, Wei YQ, Park CG, Kim CH, Huang J, Zhang W, Li Y, Yan P, Hu D; Asian Pacific Heart Association. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association. *Hypertens Res*. 2011;34:423–430. doi: 10.1038/hr.2010.259.
109. Kario K, Hoshide S, Uchiyama K, Yoshida T, Okazaki O, Noshiro T, Aoki H, Mizuno H, Matsumoto Y. Dose timing of an angiotensin II receptor blocker/calcium channel blocker combination in hypertensive patients with paroxysmal atrial fibrillation. *J Clin Hypertens (Greenwich)*. 2016;18:1036–1044. doi: 10.1111/jch.12814.
110. Kario K, Tomitani N, Kanegae H, Ishii H, Uchiyama K, Yamagiwa K, Shiraiwa T, Katsuya T, Yoshida T, Kanda K, Hasegawa S, Hoshide S. ARB/calcium-channel blocker combination on uncontrolled nocturnal hypertension evaluated by information and communication technology-based nocturnal home blood pressure monitoring – The NOCTURNE Study. *Circ J*. 2017;81:948–957.
111. Kario K, Saito I, Kushiro T, Teramukai S, Yaginuma M, Mori Y, Okuda Y, Kobayashi F, Shimada K. Persistent olmesartan-based blood pressure-lowering effects on morning hypertension in Asians: the HONEST study. *Hypertens Res*. 2016;39:334–341. doi: 10.1038/hr.2015.148.
112. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*. 2008;359:2417–2428. doi: 10.1056/NEJMoa0806182.
113. Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. *Hypertension*. 2015;66:1130–1137. doi: 10.1161/HYPERTENSIONAHA.115.06260.
114. Kario K. PREFACE: is renal denervation effective option for management of hypertension in Asia? *Curr Hypertens Rev*. 2017;13:2–5. doi: 10.2174/157340211301170619083619.
115. Kario K, Bhatt DL, Brar S, Bakris GL. Differences in dynamic diurnal blood pressure variability between Japanese and American treatment-resistant hypertensive populations. *Circ J*. 2017;81:1337–1345. doi: 10.1253/circj.CJ-16-1237.

Consensus Document on Improving Hypertension Management in Asian Patients, Taking Into Account Asian Characteristics

Kazuomi Kario, Chen-Huan Chen, Sungha Park, Chang-Gyu Park, Satoshi Hoshide, Hao-Min Cheng, Qi-Fang Huang and Ji-Guang Wang

Hypertension. 2018;71:375-382; originally published online January 8, 2018;

doi: 10.1161/HYPERTENSIONAHA.117.10238

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2018 American Heart Association, Inc. All rights reserved.

Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://hyper.ahajournals.org/content/71/3/375>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Hypertension* is online at:
<http://hyper.ahajournals.org/subscriptions/>